PE20091970A1 - Nueva sal 554 - Google Patents

Nueva sal 554

Info

Publication number
PE20091970A1
PE20091970A1 PE2009000674A PE2009000674A PE20091970A1 PE 20091970 A1 PE20091970 A1 PE 20091970A1 PE 2009000674 A PE2009000674 A PE 2009000674A PE 2009000674 A PE2009000674 A PE 2009000674A PE 20091970 A1 PE20091970 A1 PE 20091970A1
Authority
PE
Peru
Prior art keywords
cancer
refers
composition
new sal
sal
Prior art date
Application number
PE2009000674A
Other languages
English (en)
Inventor
Kay Alison Boardman
Susan Elizabeth Burns
Andrew Hornby Dobson
Brian Whitlock
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40935682&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20091970(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of PE20091970A1 publication Critical patent/PE20091970A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

SE REFIERE A LA FORMA A DE DIFUMARATO DE 4-(3-CLORO-2-FLUOROANILINO)-7-METOXI-6-{[1-(N-METILCARBAMOILMETIL)PIPERIDIN-4-IL]OXI}QUINAZOLINA, QUE TIENE UN PATRON DE DIFRACCION DE RAYOS X EN POLVO CON PICOS ALREDEDOR DE GRADOS 2-THETA: 26,4; 24,0; 23,0; 21,2; 17,3; 15,4; 14,9; 13,0; 12,4 Y 7,1. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE LA FORMA CRISTALINA Y A UN PROCEDIMIENTO DE PREPARACION DE DICHA COMPOSICION LA CUAL ES UTIL PARA EL TRATAMIENTO DE CANCER COMO CANCER DE MAMA, CANCER GASTRICO, CANCER COLORRECTAL, ENTRE OTROS
PE2009000674A 2008-05-13 2009-05-13 Nueva sal 554 PE20091970A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5270608P 2008-05-13 2008-05-13
US11063708P 2008-11-03 2008-11-03

Publications (1)

Publication Number Publication Date
PE20091970A1 true PE20091970A1 (es) 2010-02-05

Family

ID=40935682

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2009000674A PE20091970A1 (es) 2008-05-13 2009-05-13 Nueva sal 554

Country Status (31)

Country Link
US (2) US8088782B2 (es)
EP (1) EP2303276B1 (es)
JP (1) JP5739802B2 (es)
KR (1) KR20110014192A (es)
CN (1) CN102088979B (es)
AR (1) AR071714A1 (es)
AU (1) AU2009247782C1 (es)
BR (1) BRPI0912170A2 (es)
CA (1) CA2723989C (es)
CL (1) CL2009001159A1 (es)
CO (1) CO6321256A2 (es)
CR (1) CR11791A (es)
CU (1) CU23927B1 (es)
DO (1) DOP2010000346A (es)
EA (1) EA019183B1 (es)
EC (1) ECSP10010610A (es)
ES (1) ES2444128T3 (es)
HK (1) HK1152867A1 (es)
HN (1) HN2010002408A (es)
IL (1) IL209199A0 (es)
MX (1) MX2010012442A (es)
MY (1) MY183041A (es)
NI (1) NI201000197A (es)
NZ (1) NZ589883A (es)
PE (1) PE20091970A1 (es)
SA (1) SA109300290B1 (es)
SV (1) SV2010003734A (es)
TW (1) TWI443095B (es)
UY (1) UY31820A (es)
WO (1) WO2009138781A1 (es)
ZA (1) ZA201008283B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010061208A2 (en) * 2008-11-03 2010-06-03 Astrazeneca Ab Therapeutic treatment 555
MX2011011177A (es) * 2009-04-23 2011-11-18 Astrazeneca Ab Proceso para la preparacion de 4-(3-cloro-2-fluoro-anilino)-7-meto xi-6-[1-(n-metilcarbamoilmetil) piperidin-4-il] quinazolina.
EP2875020B1 (en) * 2012-07-19 2017-09-06 Boehringer Ingelheim International GmbH Process for the preparation of a fumaric acid salt of 9-[4-(3-chloro-2-fluoro-phenylamino)-7-methoxy- chinazolin-6-yloxy]-1,4-diaza-spiro[5.5]undecan-5-one
EP3226869A4 (en) * 2014-12-03 2018-07-18 Auckland UniServices, Ltd. Kinase inhibitor prodrug for the treatment of cancer
WO2019196619A1 (zh) * 2018-04-08 2019-10-17 威尚（上海）生物医药有限公司 喹唑啉衍生物盐型晶型及制备方法和应用
CN109384747A (zh) * 2018-10-26 2019-02-26 苏州立新制药有限公司 吉非替尼相关物质及其制备和检测方法
WO2022170052A1 (en) * 2021-02-05 2022-08-11 Black Diamond Therapeutics, Inc. Quinazoline derivatives, pyridopyrimidine derivatives, pyrimidopyrimidine derivatives, and uses thereof

Family Cites Families (182)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3985749A (en) * 1975-12-22 1976-10-12 Eastman Kodak Company Process for preparation of 4-aminoquinazoline
JPS5538325A (en) * 1978-09-11 1980-03-17 Sankyo Co Ltd 4-anilinoquinazoline derivative and its preparation
US4335127A (en) * 1979-01-08 1982-06-15 Janssen Pharmaceutica, N.V. Piperidinylalkyl quinazoline compounds, composition and method of use
US4332420A (en) 1980-01-11 1982-06-01 Coski William D Reciprocably supported dual drive member and features thereof
US4456359A (en) 1981-11-04 1984-06-26 Ciba-Geigy Ag Flat photographic sheet processing cassette
GB2160201B (en) 1984-06-14 1988-05-11 Wyeth John & Brother Ltd Quinazoline and cinnoline derivatives
KR910006138B1 (ko) 1986-09-30 1991-08-16 에자이 가부시끼가이샤 환상아민 유도체
IL89029A (en) 1988-01-29 1993-01-31 Lilly Co Eli Fungicidal quinoline and cinnoline derivatives, compositions containing them, and fungicidal methods of using them
US4921863A (en) * 1988-02-17 1990-05-01 Eisai Co., Ltd. Cyclic amine derivatives
CA1340821C (en) * 1988-10-06 1999-11-16 Nobuyuki Fukazawa Heterocyclic compounds and anticancer-drug reinforcing agents containing them as effective components
US5252586A (en) * 1990-09-28 1993-10-12 The Du Pont Merck Pharmaceutical Company Ether derivatives of alkyl piperidines and pyrrolidines as antipsychotic agents
DE4105503A1 (de) 1991-02-19 1992-08-20 Jenapharm Gmbh Ausgangsverbindungen zur herstellung von calcitriol sowie dessen abkoemmlingen, verfahren zur herstellung dieser ausgangsverbindungen sowie zwischenprodukte fuer dieses verfahren
US5721237A (en) 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
US5409930A (en) 1991-05-10 1995-04-25 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5710158A (en) 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
DK0517394T3 (da) * 1991-06-04 1995-08-28 Fujisawa Pharmaceutical Co Præparat mod ondartet svinelungesyge
NZ243082A (en) 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
PT100905A (pt) 1991-09-30 1994-02-28 Eisai Co Ltd Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem
US5187168A (en) 1991-10-24 1993-02-16 American Home Products Corporation Substituted quinazolines as angiotensin II antagonists
GB9300059D0 (en) 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
WO1993017682A1 (en) 1992-03-04 1993-09-16 Abbott Laboratories Angiotensin ii receptor antagonists
US5770609A (en) * 1993-01-28 1998-06-23 Neorx Corporation Prevention and treatment of cardiovascular pathologies
GB9323290D0 (en) 1992-12-10 1994-01-05 Zeneca Ltd Quinazoline derivatives
AU680004B2 (en) 1993-05-26 1997-07-17 Syntex (U.S.A.) Inc. Novel 1-phenylalkanone 5-HT4 receptor ligands
US5395846A (en) 1993-06-25 1995-03-07 Rhone-Poulenc Rorer Pharmaceuticals Inc. Amino Bi- and tri-carbocyclic aklane bis-aryl squalene synthase inhibitors
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
GB9314884D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Tricyclic derivatives
AU2096895A (en) 1994-03-07 1995-09-25 Sugen, Incorporated Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof
GB9510757D0 (en) 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
TW321649B (es) * 1994-11-12 1997-12-01 Zeneca Ltd
GB2295387A (en) 1994-11-23 1996-05-29 Glaxo Inc Quinazoline antagonists of alpha 1c adrenergic receptors
GB9424233D0 (en) 1994-11-30 1995-01-18 Zeneca Ltd Quinazoline derivatives
EP1110953B1 (en) 1995-03-30 2009-10-28 Pfizer Products Inc. Quinazoline derivatives
GB9508537D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
GB9508565D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quiazoline derivative
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
DE69613367T2 (de) 1995-04-27 2002-04-18 Astrazeneca Ab, Soedertaelje Chinazolin derivate
GB9508535D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivative
US5747498A (en) * 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US6046206A (en) * 1995-06-07 2000-04-04 Cell Pathways, Inc. Method of treating a patient having a precancerous lesions with amide quinazoline derivatives
GB9514265D0 (en) 1995-07-13 1995-09-13 Wellcome Found Hetrocyclic compounds
WO1997011692A2 (en) 1995-09-11 1997-04-03 Osteoarthritis Sciences, Inc. Protein tyrosine kinase inhibitors for treating osteoarthritis
WO1997018813A1 (en) 1995-11-22 1997-05-29 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
ATE291897T1 (de) * 1996-01-31 2005-04-15 Cosmoferm Bv Verwendung von zusammensetzungen mit stabilisierten enzymen
US6262054B1 (en) * 1996-02-01 2001-07-17 Sloan-Kettering Institute Of Cancer Research Combination therapy method for treating breast cancer using edatrexate
EP0880508B1 (en) 1996-02-13 2003-04-16 AstraZeneca AB Quinazoline derivatives as vegf inhibitors
GB9603095D0 (en) * 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
GB9603097D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline compounds
IL125954A (en) 1996-03-05 2003-06-24 Zeneca Ltd Quinazoline derivatives, processes for their preparation, pharmaceutical compositions containing them and use thereof in the manufacture of medicaments having an antiangiogenic and/or vascular permeability reducing effect
NZ332119A (en) 1996-04-12 2001-08-31 Warner Lambert Co Quinazoline compounds which are irreversible inhibitors of tyrosine kinases
GB9607729D0 (en) * 1996-04-13 1996-06-19 Zeneca Ltd Quinazoline derivatives
GB9707800D0 (en) 1996-05-06 1997-06-04 Zeneca Ltd Chemical compounds
US5795909A (en) * 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
JP4386967B2 (ja) 1996-07-13 2009-12-16 グラクソ、グループ、リミテッド プロテインチロシンキナーゼ阻害剤としての縮合複素環式化合物
US6004967A (en) * 1996-09-13 1999-12-21 Sugen, Inc. Psoriasis treatment with quinazoline compounds
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
US6225318B1 (en) * 1996-10-17 2001-05-01 Pfizer Inc 4-aminoquinazolone derivatives
EP0837063A1 (en) 1996-10-17 1998-04-22 Pfizer Inc. 4-Aminoquinazoline derivatives
GB9626589D0 (en) * 1996-12-20 1997-02-05 Prolifix Ltd Peptides
EP1014953B1 (en) 1997-03-05 2012-04-25 Sugen, Inc. Formulations for hydrophobic pharmaceutical agents
AR012634A1 (es) 1997-05-02 2000-11-08 Sugen Inc Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion
US5929080A (en) * 1997-05-06 1999-07-27 American Cyanamid Company Method of treating polycystic kidney disease
JP4327259B2 (ja) 1997-05-06 2009-09-09 ワイス・ホールディングズ・コーポレイション 多発性嚢胞腎の治療のためのキナゾリン化合物の使用
ZA986732B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
TW436485B (en) 1997-08-01 2001-05-28 American Cyanamid Co Substituted quinazoline derivatives
DE69838172T2 (de) 1997-08-22 2008-04-10 Astrazeneca Ab Oxindolylchinazolinderivate als angiogenesehemmer
HUP0004286A3 (en) 1997-11-06 2002-01-28 American Cyanamid Co Madison Use of quinazoline derivatives for producing pharmaceutical compositions for treating colonic polyps
JP4245682B2 (ja) 1997-12-25 2009-03-25 協和発酵キリン株式会社 キノリン誘導体、イソキノリン誘導体、およびシンノリン誘導体、並びに抗炎症剤および抗アレルギー剤
GB9800575D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
IL139641A0 (en) 1998-05-28 2002-02-10 Parker Hughes Inst Quinazolines for treating brain tumor
AU4851599A (en) 1998-06-30 2000-01-17 Parker Hughes Institute Method for inhibiting c-jun expression using jak-3 inhibitors
US6384223B1 (en) * 1998-07-30 2002-05-07 American Home Products Corporation Substituted quinazoline derivatives
BR9912575A (pt) 1998-07-30 2001-05-02 American Home Prod Processo para a preparação de um composto, e, composto.
WO2000009481A1 (fr) 1998-08-11 2000-02-24 Takeda Chemical Industries, Ltd. Composes d'amide cyclique, procedes de production correspondants, intermediaires correspondants et herbicides
WO2000010981A1 (en) 1998-08-21 2000-03-02 Parker Hughes Institute Quinazoline derivatives
US6184226B1 (en) 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
US6297258B1 (en) * 1998-09-29 2001-10-02 American Cyanamid Company Substituted 3-cyanoquinolines
SI2253620T1 (sl) 1998-09-29 2014-06-30 Wyeth Holdings Llc Substituirani 3-cianokinolini kot inhibitorji protein tirozin-kinaz
WO2000020402A1 (en) 1998-10-01 2000-04-13 Astrazeneca Ab Chemical compounds
TW575567B (en) 1998-10-23 2004-02-11 Akzo Nobel Nv Serine protease inhibitor
UA71945C2 (en) 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents
AU763618B2 (en) 1999-02-10 2003-07-31 Astrazeneca Ab Quinazoline derivatives as angiogenesis inhibitors
BR0008524A (pt) 1999-02-27 2001-12-18 Boehringer Ingelheim Pharma Heterociclos bicìclicos, composiçõesfarmacêuticas que contêm esses compostos, seuuso e processos para a sua prerapação
US6080747A (en) * 1999-03-05 2000-06-27 Hughes Institute JAK-3 inhibitors for treating allergic disorders
DE19911510A1 (de) 1999-03-15 2000-09-21 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
DE19911509A1 (de) * 1999-03-15 2000-09-21 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
WO2000056338A1 (en) 1999-03-19 2000-09-28 Parker Hughes Institute Quinazoline formulations and therapeutic use thereof
US6258820B1 (en) 1999-03-19 2001-07-10 Parker Hughes Institute Synthesis and anti-tumor activity of 6,7-dialkoxy-4-phenylamino-quinazolines
CA2373073A1 (en) * 1999-05-07 2000-11-16 Takeda Chemical Industries, Ltd. Cyclic compounds and uses thereof
US6518283B1 (en) 1999-05-28 2003-02-11 Celltech R&D Limited Squaric acid derivatives
US6126917A (en) * 1999-06-01 2000-10-03 Hadasit Medical Research Services And Development Ltd. Epidermal growth factor receptor binding compounds for positron emission tomography
WO2000078735A1 (de) * 1999-06-21 2000-12-28 Boehringer Ingelheim Pharma Kg Bicyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
ATE375984T1 (de) 1999-07-07 2007-11-15 Astrazeneca Uk Ltd Chinazolin derivate
GB9917408D0 (en) 1999-07-23 1999-09-22 Smithkline Beecham Plc Compounds
WO2001012227A1 (en) 1999-08-12 2001-02-22 American Cyanamid Company Nsaid and efgr kinase inhibitor containing composition for the treatment or inhibition of colonic polyps and colorectal cancer
GB9922171D0 (en) 1999-09-21 1999-11-17 Zeneca Ltd Chemical compounds
AU763242B2 (en) 1999-09-21 2003-07-17 Astrazeneca Ab Quinazoline compounds and pharmaceutical compositions containing them
GB9922173D0 (en) 1999-09-21 1999-11-17 Zeneca Ltd Chemical compounds
EP1230225A2 (en) 1999-11-01 2002-08-14 Eli Lilly And Company Pharmaceutically active 4-substituted pyrimidine derivatives
PT1244647E (pt) 1999-11-05 2006-10-31 Astrazeneca Ab Derivados de quinazolina como inibidores de vegf
CA2392554A1 (en) 1999-11-30 2001-06-28 Parker Hughes Institute Inhibitors of thrombin induced platelet aggregation
US7498335B2 (en) 2000-03-06 2009-03-03 Astrazeneca Ab Method of producing an antiangiogenic or vascular permeability reducing effect
US20030152572A1 (en) * 2000-04-06 2003-08-14 Yoshimi Homma Diagnostic and therapeutic agents for rheumatoid arthritis
GB0008368D0 (en) 2000-04-06 2000-05-24 Astrazeneca Ab Combination product
BR0109828A (pt) 2000-04-07 2002-12-17 Astrazeneca Ab Composto, processo para a prepapação do mesmo ou de um sal deste, composição farmacêutica, uso do composto ou de um sal deste farmaceuticamente aceitável, e, método para a produção de um efeito antiangiogênico e/ou redutor da permeabilidade vascular em um animal de sangue quente em necessidade de tal tratamento
CN1251671C (zh) 2000-05-19 2006-04-19 武田药品工业株式会社 β分泌酶抑制剂
UA73993C2 (uk) 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
SK2142003A3 (en) 2000-08-21 2003-07-01 Astrazeneca Ab Quinazoline derivatives, process for their preparation, pharmaceutical composition comprising same and their use
US20020082270A1 (en) * 2000-08-26 2002-06-27 Frank Himmelsbach Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases
US6617329B2 (en) * 2000-08-26 2003-09-09 Boehringer Ingelheim Pharma Kg Aminoquinazolines and their use as medicaments
US6740651B2 (en) * 2000-08-26 2004-05-25 Boehringer Ingelheim Pharma Kg Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases
US6653305B2 (en) * 2000-08-26 2003-11-25 Boehringer Ingelheim Pharma Kg Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them
DE10042060A1 (de) 2000-08-26 2002-03-07 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
US6656946B2 (en) * 2000-08-26 2003-12-02 Boehringer Ingelheim Pharma Kg Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases
DE10042062A1 (de) 2000-08-26 2002-03-07 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Hertellung
DE10042058A1 (de) 2000-08-26 2002-03-07 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
DE10042061A1 (de) 2000-08-26 2002-03-07 Boehringer Ingelheim Pharma Bicyclische Heterocyclen,diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
DE10042059A1 (de) 2000-08-26 2002-03-07 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
EP1719770A3 (en) 2000-09-21 2008-03-05 Smithkline Beecham Plc Quinoline derivatives as antibacterials
WO2002030924A1 (en) 2000-10-13 2002-04-18 Astrazeneca Ab Quinazoline derivatives with anti-tumour activity
NZ526003A (en) 2000-10-20 2005-09-30 Biocryst Pharm Inc Biaryl compounds as serine protease inhibitors
AU2002212436A1 (en) 2000-10-25 2002-05-06 Astrazeneca Ab Quinazoline derivatives
US20030158196A1 (en) * 2002-02-16 2003-08-21 Boehringer Ingelheim Pharma Gmbh Co. Kg Pharmaceutical compositions based on anticholinergics and EGFR kinase inhibitors
US7067532B2 (en) 2000-11-02 2006-06-27 Astrazeneca Substituted quinolines as antitumor agents
AU2002221115A1 (en) * 2000-12-11 2002-06-24 Takeda Chemical Industries Ltd. Medicinal compositions having improved absorbability
AUPR201600A0 (en) 2000-12-11 2001-01-11 Fujisawa Pharmaceutical Co., Ltd. Quinazolinone derivative
DE10063435A1 (de) 2000-12-20 2002-07-04 Boehringer Ingelheim Pharma Chinazolinderviate,diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
US7019012B2 (en) * 2000-12-20 2006-03-28 Boehringer Ingelheim International Pharma Gmbh & Co. Kg Quinazoline derivatives and pharmaceutical compositions containing them
GB0101577D0 (en) 2001-01-22 2001-03-07 Smithkline Beecham Plc Compounds
WO2002062767A1 (fr) 2001-02-07 2002-08-15 Sumitomo Pharmaceuticals Company, Limited Nouveaux derives de quinazoline
NZ516873A (en) 2001-02-12 2003-11-28 Warner Lambert Co Compositions containing retinoids and erb inhibitors and their use in inhibiting retinoid skin damage
ATE475652T1 (de) * 2001-02-21 2010-08-15 Mitsubishi Tanabe Pharma Corp Chinazolinderivate
KR100849839B1 (ko) 2001-02-23 2008-08-01 머크 앤드 캄파니 인코포레이티드 Ｎ-치환된 비-아릴-헤테로사이클릭 ｎｍｄａ/ｎｒ2ｂ 길항제 및 이를 포함하는 약제학적 조성물
US6562319B2 (en) * 2001-03-12 2003-05-13 Yissum Research Development Company Of The Hebrew University Of Jerusalem Radiolabeled irreversible inhibitors of epidermal growth factor receptor tyrosine kinase and their use in radioimaging and radiotherapy
CA2441492C (en) 2001-03-23 2011-08-09 Bayer Corporation Rho-kinase inhibitors
WO2002092579A1 (en) 2001-05-14 2002-11-21 Astrazeneca Ab 4-anilinoquinazoline derivatives
WO2002092578A1 (en) 2001-05-14 2002-11-21 Astrazeneca Ab Quinazoline derivatives
WO2002092577A1 (en) 2001-05-14 2002-11-21 Astrazeneca Ab Quinazoline derivatives
AR033765A1 (es) 2001-05-22 2004-01-07 Syngenta Participations Ag Procedimiento para la preparacion de derivados 3-alquil-3h-isobenzofuran-1-ona 7-sustituidos.
WO2002094790A1 (fr) * 2001-05-23 2002-11-28 Mitsubishi Pharma Corporation Compose heterocyclique condense et son utilisation medicale
EP1408980A4 (en) 2001-06-21 2004-10-20 Ariad Pharma Inc NEW QUINAZOLINES AND THEIR USE
US20050043336A1 (en) 2001-11-03 2005-02-24 Hennequin Laurent Francois Andre Quinazoline derivatives as antitumor agents
GB0126433D0 (en) 2001-11-03 2002-01-02 Astrazeneca Ab Compounds
GB0126879D0 (en) * 2001-11-08 2002-01-02 Astrazeneca Ab Combination therapy
GB0128108D0 (en) 2001-11-23 2002-01-16 Astrazeneca Ab Therapeutic use
GB0128109D0 (en) 2001-11-23 2002-01-16 Astrazeneca Ab Therapeutic use
EP1465632A1 (en) 2001-12-12 2004-10-13 Pfizer Products Inc. Quinazoline derivatives for the treatment of abnormal cell growth
JP2003246780A (ja) 2001-12-17 2003-09-02 Eisai Co Ltd 含窒素芳香環化合物の製造方法
RU2365588C2 (ru) 2002-02-01 2009-08-27 Астразенека Аб Хиназолиновые соединения
DE10204462A1 (de) * 2002-02-05 2003-08-07 Boehringer Ingelheim Pharma Verwendung von Tyrosinkinase-Inhibitoren zur Behandlung inflammatorischer Prozesse
EP1481971B1 (en) * 2002-02-06 2011-11-16 Ube Industries, Ltd. Process for producing 4-aminoquinazoline compound
US7927613B2 (en) * 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
TWI324597B (en) * 2002-03-28 2010-05-11 Astrazeneca Ab Quinazoline derivatives
US6924285B2 (en) * 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
IL164167A0 (en) * 2002-03-30 2005-12-18 Boehringer Ingelheim Pharma 4-(N-phenylamino)-quinazolines/ quinolines as tyrosine kinase inhibitors
US20040044014A1 (en) * 2002-04-19 2004-03-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof
WO2003101491A1 (fr) * 2002-06-03 2003-12-11 Mitsubishi Pharma Corporation Moyens preventifs et/ou therapeutiques destines a des sujets presentant l'expression ou l'activation de her2 et/ou egfr
CN1192564C (zh) * 2002-06-06 2005-03-09 华为技术有限公司 开放最短路径优先协议第五类链路状态通告分组刷新的方法
US6900206B2 (en) * 2002-06-20 2005-05-31 Bristol-Myers Squibb Company Indole, azaindole and related heterocyclic sulfonylureido piperazine derivatives
AT6168U1 (de) * 2002-07-15 2003-05-26 Blum Gmbh Julius Scharnier
US6890549B2 (en) 2002-08-19 2005-05-10 Art Jen Complexus, Inc. Compositions comprising dietary fat complexer and methods for their use
WO2004018430A1 (ja) * 2002-08-23 2004-03-04 Kirin Beer Kabushiki Kaisha ＴＧＦβ阻害活性を有する化合物およびそれを含んでなる医薬組成物
JPWO2004060400A1 (ja) * 2003-01-06 2006-05-11 那波　宏之 上皮成長因子受容体を分子標的とする抗精神病薬
DE10300098A1 (de) * 2003-01-07 2004-07-15 Bayer Ag Kupfer-Carben-Komplexe und ihre Verwendung
DE10300097A1 (de) * 2003-01-07 2004-07-22 Bayer Ag Kupfer-Komplexe und ihre Verwendung
JP2006515871A (ja) 2003-01-23 2006-06-08 ティー．ケイ． シグナル リミテッド 上皮増殖因子受容体チロシンキナーゼの不可逆阻害剤ならびにその使用
DE10315917A1 (de) * 2003-04-08 2004-11-18 Schwarz Pharma Ag Hochreine Basen von 3,3-Diphenylpropylaminmonoestern
GB0309009D0 (en) 2003-04-22 2003-05-28 Astrazeneca Ab Quinazoline derivatives
GB0309850D0 (en) 2003-04-30 2003-06-04 Astrazeneca Ab Quinazoline derivatives
CA2533345A1 (en) * 2003-07-29 2005-02-10 Astrazeneca Ab Piperidyl-quinazoline derivatives as tyrosine kinase inhibitors
GB0317665D0 (en) * 2003-07-29 2003-09-03 Astrazeneca Ab Qinazoline derivatives
ATE395346T1 (de) 2003-09-16 2008-05-15 Astrazeneca Ab Chinazolinderivate als tyrosinkinaseinhibitoren
GB0321648D0 (en) 2003-09-16 2003-10-15 Astrazeneca Ab Quinazoline derivatives
US20070032508A1 (en) 2003-09-16 2007-02-08 Bradbury Robert H Quinazoline derivatives as tyrosine kinase inhibitors
US20070037837A1 (en) * 2003-09-19 2007-02-15 Hennequin Laurent Francois A Quinazoline derivatives
CN1882569B (zh) * 2003-09-19 2010-09-29 阿斯利康(瑞典)有限公司 喹唑啉衍生物
JP2007506716A (ja) * 2003-09-25 2007-03-22 アストラゼネカ アクチボラグ キナゾリン誘導体
AR051444A1 (es) * 2004-09-24 2007-01-17 Centocor Inc Proteinas derivadas de inmunoglobulina especifica de il-23p40, composiciones, epitopos, metodos y usos
AU2006278596A1 (en) * 2005-08-04 2007-02-15 Novartis Ag Salts of vildagliptin
US20060223820A1 (en) * 2006-03-21 2006-10-05 Chemagis Ltd. Crystalline aripiprazole salts and processes for preparation and purification thereof
KR20080028813A (ko) * 2006-09-27 2008-04-01 삼성전자주식회사 통신 시스템에서 파일럿 채널 탐색 제어 장치 및 방법

Also Published As

Publication number Publication date
EA201001773A1 (ru) 2011-06-30
NI201000197A (es) 2012-11-07
BRPI0912170A2 (pt) 2015-10-13
EA019183B1 (ru) 2014-01-30
ES2444128T3 (es) 2014-02-24
IL209199A0 (en) 2011-01-31
CA2723989A1 (en) 2009-11-19
EP2303276B1 (en) 2013-11-13
AU2009247782B2 (en) 2012-06-28
MX2010012442A (es) 2011-10-11
SV2010003734A (es) 2011-03-15
AR071714A1 (es) 2010-07-07
CU23927B1 (es) 2013-07-31
MY183041A (en) 2021-02-08
CA2723989C (en) 2017-04-25
DOP2010000346A (es) 2011-01-15
CO6321256A2 (es) 2011-09-20
AU2009247782A1 (en) 2009-11-19
CL2009001159A1 (es) 2010-06-11
US8088782B2 (en) 2012-01-03
WO2009138781A1 (en) 2009-11-19
CR11791A (es) 2011-01-12
NZ589883A (en) 2012-06-29
HK1152867A1 (en) 2012-03-16
EP2303276A1 (en) 2011-04-06
UY31820A (es) 2010-01-05
CN102088979B (zh) 2013-10-16
CN102088979A (zh) 2011-06-08
SA109300290B1 (ar) 2013-05-18
ZA201008283B (en) 2011-08-31
US20120035363A1 (en) 2012-02-09
JP2011520857A (ja) 2011-07-21
KR20110014192A (ko) 2011-02-10
AU2009247782C1 (en) 2013-09-19
US8404839B2 (en) 2013-03-26
TW201008923A (en) 2010-03-01
US20090286982A1 (en) 2009-11-19
ECSP10010610A (es) 2010-12-30
HN2010002408A (es) 2013-05-06
TWI443095B (zh) 2014-07-01
CU20100222A7 (es) 2011-11-15
JP5739802B2 (ja) 2015-06-24

Similar Documents

Publication Publication Date Title
PE20091970A1 (es) Nueva sal 554
PE20080663A1 (es) Terapia tumoral con una combinacion de anticuerpos anti-her2
TR201907783T4 (tr) Benzosulfonamit türevleri, bileşimleri ve kanser hücrelerinin metastazının önlenmesinde kullanımları.
TW201129570A (en) Spiro-oxindole MDM2 antagonists
PH12014502419A1 (en) Specific binding proteins and uses thereof
CR20170097A (es) Compuestos terapéuticamente activos y sus métodos de uso (divisional)
CL2007002994A1 (es) Compuestos derivados heterociclicos que contienen sulfamoilo, inhibidores de hsp90; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de mama, de colon y prostata, entre otros.
CL2008001813A1 (es) Compuestos derivados de quinolin-3-carbonitrilo sustituidos con piperazina; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como artritis, inflamacion, cancer entre otras (div. sol. 266-04).
CL2008001047A1 (es) Compuestos derivados de difenil-dihidro-imidazopiridinonas; inhibidores de mdm2-p53;composicion farmaceutica;y uso para preparar un medicamento destinado al tratamiento o control de tumores solidos,tales como:tumores de mama.de colon,de pulmon o de prostata.
PE20141381A1 (es) Terapia de combinacion que comprende un inhibidor de cdk4/6 y un inhibidor de pi3k para el uso en el tratamiento de cancer
UA109464C2 (uk) Спірооксіндольні антагоністи mdm2
PE20070207A1 (es) Tratamiento combinado de los tumores que expresan el her
EP2254899A4 (en) BLOCKING METASTASES OF CANCER CELLS AND NOVEL COMPOSITIONS THEREFOR
NI201200175A (es) Métodos de tratamiento de cáncer de vejiga
MX2012007367A (es) Compuestos substituidos de imidazopiridinilo-aminopiridina.
DOP2012000063A (es) (heteroarilmetil) tiohidantoinas sustituidas como drogas anticancer
CL2008001076A1 (es) Compuestos derivados de sulfonamida; composicion farmaceutica; y uso en el tratamiento del cancer.
CL2008000670A1 (es) Compuestos derivados de tiazolidindionas y oxazolidindionas sustituidas; composicion farmaceutica; proceso de preparacion de la composicion farmaceutica; y uso en el tratamiento de enfermedades tales como artritis reumatoide, epoc, cancer, entre otras.
AR078824A1 (es) Compuesto de cabazitaxel y sus usos
MX2012010434A (es) Compuestos y composiciones novedosas para atacar a las celulas madre del cancer.
WO2014089177A3 (en) Compounds, conjugates and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines
DOP2010000302A (es) Antagonistas de la trayectoria hedgehog de ftalazina disustituida
CL2008001658A1 (es) Composicion farmaceutica que comprende mesilato de imatinib amorfo y un principio de formulacion que estabiliza la forma amorfa; y su uso para tratar leucemia mieloide cronica avanzada y recientemente diagnosticada, leucemia mielomonocitica cronica, glioblastoma multiforme, entre otras.
CR20110479A (es) Combinaciones farmaceuticas que comprenden rdea 119/bay 869766 para el tratamiento de canceres especificos
CL2011002774A1 (es) Combinacion farmaceutica que comprende cabazitaxel y capecitabina, en forma de base, sal, hidrato o solvato; uso para el tratamiento del cancer de mama metastasico.

Legal Events

Date Code Title Description
FC Refusal